Shortages and Supply: Why Ozempic Is Protected for Diabetes?

Surging demand has caused supply pressures. Here's why some products are prioritised for people with diabetes.

Key takeaways

• High demand has at times strained GLP-1 supply.
• Diabetes supply of some products has been prioritised.
• Off-label use for weight loss can worsen shortages for diabetes patients.
• Supply guidance changes — check current advice.

When a medicine becomes famous, demand can outrun supply — and few medicines have become famous quite as fast as the GLP-1 family. Supply pressure has been a real part of their story, and it quietly explains some of the rules and frustrations people run into when trying to fill a prescription.

If you've ever been told your usual product is 'out of stock' or that a pharmacy can't get hold of it, it can feel personal and worrying. It usually isn't personal at all. It's the knock-on effect of a global surge in demand meeting the limits of how quickly these medicines can be made.

Why shortages happened in the first place

Rapid, widespread demand — driven in large part by interest in weight management — has at times outpaced how fast manufacturers can produce these medicines, leading to supply pressures across several GLP-1 products. These pens are complex to make, so production can't simply be turned up overnight to match a spike in demand.

It's an unusual situation: a shortage caused not by a medicine failing, but by it succeeding far beyond what anyone planned for. That's small comfort if you're affected, but it does explain why the response has focused on sharing limited stock fairly.

Why diabetes comes first for some products

To protect people who depend on these medicines for type 2 diabetes, guidance has at times asked that certain products — Ozempic among them — be reserved for their licensed diabetes use, rather than being prescribed off-label for weight loss while supplies are tight.

The reasoning is about priority rather than worth. For someone managing type 2 diabetes, a GLP-1 may be an important part of keeping blood sugar steady, and an interruption can have real consequences. So when stock is limited, steering a diabetes-licensed product towards diabetes patients is a way of making sure the people who most rely on it aren't left without. You can read more about why the same drug carries different licences in Ozempic vs Wegovy: One Drug, Two Licences.

Who manages all this

Medicine supply in the UK is monitored and managed nationally, with the Department of Health and Social Care and the MHRA working with manufacturers and the NHS to track shortages and issue guidance to prescribers and pharmacists. When a serious shortage arises, formal notices can be issued to help clinicians manage it consistently across the country.

What it means for you in practice

If your product is hard to come by, the most useful step is simply to talk to your prescriber or pharmacist early — before you run low — rather than hunting for it elsewhere. They'll know the current local picture and can talk through the options, which might include an alternative within the same family if that's clinically appropriate for you.

It's also worth being wary of any seller who suddenly has plenty of a 'scarce' medicine to offer outside the normal system. Shortages are exactly the moment when unregulated and falsified products tend to appear — there's more on staying safe in Getting a GLP-1 Privately in the UK.

What it means for you If a particular product is hard to get, that's about supply, not about you. A prescriber or pharmacist can explain the current options and help you avoid running out.

And it keeps changing

Supply, and the guidance wrapped around it, shifts over time as manufacturing catches up and demand settles — so today's position may look quite different in a year. It's always worth checking the latest advice rather than relying on what was true a few months ago.

Sources

• MHRA
• NHS
• Department of Health and Social Care (DHSC)